Skip to main content

Market Overview

Spectrum Pharmaceuticals Gains 5% After Company Confirms FDA Review Of New Drug


Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) were trading higher by nearly 5 percent late Friday morning after the company announced that the U.S. Food and Drug Administration (FDA) has accepted its EOquin for New Drug Application (NDA) for review.

EOquin (apaziquone for intravesical instillation) is used for the treatment of non-muscle invasive bladder cancer.

Spectrum Pharmaceuticals added that the FDA indicated it plans to hold an advisory committee regarding the NDA and has set a target action date under the Prescrpition Drug User Fee Act (PDUFA) for December 11, 2016.


Related Articles (SPPI)

View Comments and Join the Discussion!

Posted-In: Apaziquone Cancer Therapies EOquin New Drug ApplicationNews FDA Movers

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at